Oragenics Reports Positive Results of an Independent ProBiora3 Study
Oragenics, Inc. (NYSE MKT:OGEN) announced today the successful completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3®, in early childhood development of dental caries in preschool children living in low socioeconomic, multicultural areas.
The study was conducted under the guidance of Professor Svante Twetman, a world- renowned probiotics expert, with the results published in a peer reviewed journal(1). The study employed a randomized double-blind placebo-controlled design consisting of 138 healthy children ranging from two to three years in age. The children were placed into groups that were administered once a day either chewable tablets containing ProBiora3® or a placebo tablet. In conjunction with this study, parents were further instructed to thoroughly brush the children’s teeth in each group twice daily with fluoride toothpaste. Study duration was one year with 66% compliance.
Overall, the ProBiora3® administered group observed statistically significant lower dental caries increments than in the placebo group, 0.2 vs. 0.8 (p<0.05). The risk reduction for caries development was 0.47 (95% CI 0.24-0.98), with no side effects being reported among either group. “These results suggest that administration of ProBiora3® in conjunction with daily use of fluoride toothpaste significantly reduces development of early childhood dental caries in preschool children,” stated Dr. Twetman’s team.
Dr. Fred Telling, Chairman of the Board of Oragenics said, “We are excited by the successful completion of this study and the beneficial results observed in preschool children, with no harmful side effects being observed. While further studies are needed to optimize dose dependent responses for ProBiora3®, this study is very promising for the use of ProBiora3® against early childhood development of dental caries.”
(1) Trifa Hedayati-Hajikand, Ulrika Lundberg, Catarina Eldh and Svante Twetman, “Effect of probiotic chewing tablets on early childhood caries – a randomized controlled trial.” BMC Oral Health, 2015 15:112
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States.
For more information about Oragenics, visit www.oragenics.com.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, any inability to obtain or delays in FDA approval for future clinical studies and testing, the future success of our studies and testing and any inability to also achieve favorable results in human studies, our ability to successfully develop and commercialize products, the financial resources available to us to continue research and development, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.